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http:WHAT THIS PAPER ADDS
This paper offers a method for endovenous valve transfer for chronic deep venous insufﬁciency; a speciﬁc stent
design to optimise and simplify the technique; and an assessment of patency, competence, safety, and efﬁcacy
in 16 sheep and a small human pilot study. It also highlights the challenges of venous valve transfer in chronic
deep venous insufﬁciency.Objectives: The aims of the study were to test the safety and efﬁcacy of a custom-made endovenous valve
transfer stent, and delivery system in animals and humans.
Methods: The internal jugular veins of 16 sheep, weighing 45e55 kg, were used. A segment of vein with venous
valve was enclosed circumferentially with a barbed stent. This segment from the internal jugular vein was
introduced and deployed remotely into the contralateral internal jugular vein. Harvesting occurred acutely (one
sheep) and at 1, 3, and 6 months postoperatively (ﬁve sheep per group). Operative competence testing,
histological and scanning electron microscopic (SEM) examinations were performed. Four males with recalcitrant
ulcers (mean age of 22 years) had axillary veins transferred from the popliteal vein and were followed for a mean
of 3.8 years.
Results: At harvest, all the transferred valves were competent, with no evidence of thrombosis, tilting, endoleak,
or migration with normal macroscopic and SEM ﬁndings. Although only 50% of the ulcers completely healed in
humans, the remainder were improved, with all valves being competent and patent.
Conclusions: Endovenous valve transfer with a custom-made circumferential stent produces near perfect results
in sheep and encouraging results in a small pilot study.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved
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Chronic deep venous insufﬁciency (CDVI) imposes an
enormous clinical and ﬁnancial burden on the commu-
nity,1,2 with current treatment modalities being unsatisfac-
tory.3 The syndrome relates to venous valve dysfunction or
obstruction leading to venous reﬂux, outﬂow congestion,
and venous hypertension.4 It is well known that, in the long
term, this may lead to varicose veins, chronic venous ulcers,
and other related conditions. For patients with persistent
deep venous symptoms in which other treatment modal-
ities (compression therapy, ablative procedures) are
exhausted, venous valves repaired directly or by venous
valve transposition in the deep system have produced
encouraging results in the short and long term.5e12responding author. R.J. Lane, Vascular Specialists Investigations and
ement, Suites 13 and 14, Greenwich Square, 130e134 Paciﬁc
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//dx.doi.org/10.1016/j.ejvs.2013.05.013However, these procedures require considerable surgical
skill, are not commonly performed, and may be associated
with potentially serious complications, speciﬁcally deep
venous thrombosis and pulmonary embolism.12 Addition-
ally, there are also problems related to valve ring dilatation
in the transposed vein and subsequent incompetence in the
long term.6 A venous valve delivered remotely and perhaps
percutaneously may alleviate some of these logistical difﬁ-
culties, hence the development of artiﬁcial (polymer,
biosynthetic, and autogenous) venous valves with prom-
ising results in animals, although thrombosis (5e80%) and
cusp thickening related to the use of a foreign body are to
be addressed.13e17
An autologous endovenous valve transfer stent (EVTS)
would appear to be a logical improvement, taking advan-
tage of available vascular stent developments and deploy-
ment technology. There are encouraging results of stented
autologous venous valve transfers in both goats18 and
dogs.19e21 The present study uses a custom design in which
a stent is placed around a native vein with a functional
valve. The stent, with mounted valve, is then transferred
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formed using standard surgical techniques and readily
available endovascular equipment. The results of this
venous valve transfer system in animals and a small pilot
study in humans are presented.
METHODS
Subjects
For the animal study, 16 sheep weighing between 45 to
55 kg were included. For the human pilot study, four men
were included. The demographics are shown in Table 1. The
CEAP classiﬁcation was C6 ES AD PRO n ¼ 3 and C6 Ep AD PRO
n ¼ 1. The investigative protocols in both animals
(NSCCH1039) and humans (Protocol EVTS AV005 [Clinical
Trial Notiﬁcation 0509-174M]) were approved by the local
institutional review board of the Northern Sydney Central
Coast Health service. The animal trial was conducted in
accordance with good laboratory practice and international
guidelines in animal research, and the human trials were
performed in accordance with the ethical principles as
described in the Declaration of Helsinki. Written consent
was obtained from all patients in the human pilot trial.
Materials
The EVTS (9  24 mm, including barbs) (Fig. 1a) was made
by AllVascular (St Leonards, NSW, Australia) and the intro-
ducing system produced by Cook (Bloomington, IN, USA).
There are very speciﬁc characteristics of a venous valve
transfer stent that would separate it from commercially
available devices designed to expand a lumen rather than
act as a carrier of a valve. The optimal design encompasses
an exo-stent with a variable diameter, i.e., placed circum-
ferentially around the valve-containing vein segment, usu-
ally in the axilla or contralateral profunda vein. The venous
connections to the stent would need to be ﬂuid sealed to
prevent endoleak, and the stent itself have a minimal blood
interface to minimise thrombogenicity as the barbs have
blood contact. Additionally, the device, as well as being
crimpable to minimise the diameter proﬁle of the intro-
ductory system, would optimally be expandable to maxi-
mise adhesion to the recipient wall.
For optimal wall ﬁxation, ﬁne barbs (3 mm in length)
were designed to penetrate the donor wall, as well as to
impinge on the recipient wall. These also could be used asTable 1. Human patient results.
Initials Sex Age
(y)
Previous
treatment
(A,B,C,D,E,F)a
Primary/secondary
(1/2)b
Ulcer
time
(y)
JM M 67 ABCDEF 2 34
JG M 75 ABCDEF 2 25
GW M 46 ABCE 1 15
KP M 58 ABCEF 2 9
Note. M ¼ male.
a A ¼ compression; B ¼ stripping; C ¼ perforator ligation; D ¼ skin g
b 1 ¼ primary venous disease; 2 ¼ secondary venous disease.an easy way to connect the ends of the venous valve-
containing segment onto the stent. In addition, the body
of the stent had a zigzag pattern, which creates high fric-
tional resistance between the external surface of the stent
and the recipient vein wall. Furthermore, in the assessment
of the recipient diameter, a 2-mm expansion coefﬁcient
was considered optimal, i.e., if the axillary vein required a
10-mm stent, an 8-mm recipient site was selected.
The length of the EVTS was 20 mm to avoid tilting within
the recipient vein and to minimise endoleak, i.e., an artiﬁ-
cial passage between the donor and recipient vein. In the
clinical situation the device needs to be small enough to
avoid crossing major tributaries, again precipitating endo-
leak, but also avoiding haemodynamic disturbances.Animal pre-surgical protocol
Two portable, battery-powered duplex scanners (Sonosite,
Bothell, WA, USA) and Terason 2000 (Terason Ultrasound,
Burlington, MA, USA) were used to identify venous valves in
the jugular system. A completely competent segment or a
segment with very minimal reﬂux were acceptable.Animal surgical procedure
The sheep were anaesthetised with intravenous thio-
pentone, following which they were intubated and venti-
lated. Both internal jugular veins were isolated and the
valves identiﬁed (Fig. 1b). A nitinol stent was placed around
the competent valve (Fig. 1c) and the length of the vein
ﬁxed with sutures to prevent longitudinal shortening.
Further, 5.0 Prolene sutures were used to adjust the
diameter of the EVTS. The vein was then harvested and,
similarly, sutures were used to join the end of the EVTS to
the contained vein segment. The EVTS and the venous valve
segment (Fig. 1d) were then placed into the ﬂared end of
the introducing system and a pusher used to position the
stented valve at the front end of the introducing system.
After controlling the recipient vein with Vessiloops, a
venotomy allowed remote deployment of the EVTS and
valve segment. Competence was tested by leaving the
venotomy open. The absence of back ﬂow when the distal
Vessiloop was released indicated competence (Fig. 2).
Postoperatively, the sheep were returned to their pen and
Clexane 40 mg (Sanoﬁ-Avantis, Macquarie Park, NSW,
Australia) given subcutaneously daily for 1 week. The veinsUlcer size
(cm2)
Postoperative Ulcer follow
up time (y)
Ulcer size
(cm2)Patent Competent
45 Yes Yes 2.3 18
16 Yes Yes 4 4
16 Yes Yes 4.8 0
Widespread
superﬁcial
Yes Yes 4.2 0
rafting; E ¼ sclerotherapy; F ¼ hyperbaric oxygen.
Figure 1. (a) The basic design of a venous valve transfer stent. The sharp barbs at each end penetrate the donor wall and impinge the
recipient wall. (b) Identiﬁcation of venous valves via external appearance with competence tested via the milking technique. (c) Stent
placement around the valve. (d) Stent encasing a vein containing a competent valve.
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1 month, 3 months, and 6 months respectively. At these
times the ﬁndings were recorded.Human protocol
A pilot study in four humans was conducted to illustrate the
modiﬁcation of the animal method to humans. All patients
had a long history of chronic leg ulceration due to CDVI. All
standard treatment modalities had been exhausted
(Table 1) and antibiotics were used if appropriate accordingFigure 2. Testing the competence of the transferred valve (1)
shows no backbleeding through the insertion site (2).to sensitivity. The pre-operative assessment included
bacteriological swabs of the active ulcers and duplex ul-
trasound (Logic 9G; GE, Milwaukee, WI, USA) of the upper
limbs (potential competent donor valves) and affected
lower limbs (recipient site). The diameters of the donor
valves were recorded and suitable open popliteal venous
segments were identiﬁed. The venous function was
assessed with infrared photoplethysmographs22 with the
waveform during exercise indicative of calf muscle pump.
Ascending venography in the arms further correlates suit-
able valves with ascending and descending venography in
the affected limb to further assess reﬂux and potential
recipient sites. The optimal site is a long, smooth-walled
popliteal venous segment without signiﬁcant tributaries or
entering collaterals. Under general anaesthetic the axillary
veins containing the valve were externally stented and
tested to be competent. The axillary veins were then
ligated. The above-knee popliteal vein was dissected and
controlled with Vessiloops, and through a small longitudinal
incision in the above-knee popliteal the lower popliteal and
tibial systems were manually dilated (using dilators) and the
EVTS deployed proximal to the tibio peroneal trunk
(approximately 15 cm from venotomy). In one limb an
operative descending venogram (Fig. 3) demonstrated a
small endoleak, as well as a patent and competent valve. All
patients received anticoagulation therapy consisting of
heparin and postoperative Warfarin starting on day 1 with a
target range of 2.5e3.5. Daily Clexane 1.5 mg/kg was given
until the international normalised ratio was sufﬁcient.
Figure 3. Operative descending venogram showing a patent and
competent venous valve (1) with slight bulging and prolapse of the
valve cusps. There is a type 1 venous endoleak (2) due to a trib-
utary entering alongside the stent. There is a duplicated and
insufﬁcient popliteal vein (3) running alongside the stented vein.
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The aim of deployment site selection was to create a
competent segment as close as feasible to the ulceration
area without obstructing major tributaries. Both venog-
raphy and duplex may fail to deﬁne tributary entry, which is
often related to multiple smaller collaterals induced by
proximal venous obstruction and hence the possibility of a
minor endoleak,Figure 4. Light microscopic sections at 6 months of the sheep
donor valve showing the vein lumen (1), transferred valve with
endothelium (2), recipient wall with endothelium not discernible
(3), and the stent struts (4).End points
Animal study. An intra-operative and postoperative
assessment were made of patency, competence, throm-
bosis, tilting of the valve, migration, endoleak, ﬁxation,
stent visibility, and untoward effects of the remote access
venotomy. This had been 1.5-cm long and closed by direct
suture. Scanning electron microscopy (SEM) and light mi-
croscopy were performed on a total of seven spec-
imensdone at 1 month, two at 2 months, and four at 6
months.
Human study. End points included postoperative ultrasonic
assessment of valve patency and competency. The clinical
follow-up times were immediate postoperative, at 1 month,
3 months, and 6 months, and long term (>1 year). Ultra-
sonic examination was performed by an experienced
vascular sonographer.RESULTS
Animal study
All 16 sheep specimens had no macroscopic evidence of
thrombosis, EVTS migration, or tilting, and no stents were
visible (i.e., no nitinol protruding through the lumen). The
pathology examination of multiple sections showed micro-
scopically that there was no evidence of thrombosis, or
inﬂammatory changes or evidence of intimal hyperplasia or
cellular inﬁltrate (Fig. 4). The SEM showed no thrombosis,
cusp changes, and normal endothelial cellular characteris-
tics (Fig. 5).Human study
On average, the procedure time was 2.5 hours. All human
patients showed a decrease in ulcer size, with complete
healing of the ulcer in two patients (50%). All valves
remained patent and competent during follow up. Two
valves showed signs of a “venous endoleak” due to a large
tributary entering alongside the stented valve at operation,
but were not detectable at any time postoperatively on
duplex. The tributaries remained patent and there was no
evidence of peri-graft haematoma. The results of the hu-
man pilot study are shown in Tables 1 and 2.DISCUSSION
The results of both animal and initial human studies show
that venous valves can be transferred from one site to
another endovenously with safety. The transferred valves
are durable with patency and competency maintained for
up to 6 months in sheep and up to 4.8 years in humans.
Fifty per cent of all ulcers completely healed with a 67%
area reduction in the remainder. These experiments conﬁrm
similar experiments in goats and dogs using standard
stents.18,21,23 The basic techniques differ little from
Figure 5. Scanning elctromicrographs of the endothelium showing
normal healthy endothelium of the recipient valve.
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was developed to test modiﬁcation of standard stent
morphology and function to facilitate venous valve har-
vesting and transfer.Alternative approaches
There is ample experimental and clinical evidence that
creating deep venous valvular competence signiﬁcantly
improves the sequelae of chronic venous hyperten-
sion.5,6,10,12 A novel technique described by Maleti creates a
neovalve by dissecting the vein wall to obtain ﬂaps.
Although a venotomy is required the technique offers an
alternative in extensively affected post-thrombotic veins.
The results are promising.24 This technique may be possible
to be used in unison with venous valve transfer as one
competent valve transfer produced complete healing in
50% of limbs.
The greatest challenge for the post-phlebitic limb is to
provide a minimally invasive procedure of widespread
applicability and to avoid long-term deterioration following
free valve transfer. Speciﬁcally, Taheri et al.25 note a pro-
gressive dilatation of the valve ringwith deterioration of valve
function following brachial valve transfer to the femoral vein.
Bry et al.11 transferred axillary valves to the popliteal for
better size matching as it was thought that the popliteal vein
was the gatekeeper to the calf. Hence, the logic of this pro-
tocol of a stented transferred valve to the popliteal fossa.
The advantages of biosynthetic valves comprised of a
stainless steel stent and barbs with a sheet of small intes-
tinal submucosa introduced percutaneously14 under localTable 2. Human patient valve transfer details.
Initials Harvest Ø (mm)
(left axillary vein)
Target site Target Ø
(mm)
JM 7, 9 Right popliteal vein 8, 6
JG 7 Left popliteal vein 7
GW 8 Left popliteal vein 7
KP 7 Right popliteal vein 5.5anaesthetic have wide applicability and, theoretically, it
may be possible to implant an unlimited number of valves.
There have been notable advances, as described by Pavcnik
et al.14 In practice, however, thickening of the cusps in these
designs requires inertial forces to be much higher to open
and close compared with native valves, and this may induce
cusp wall adherence. This limits the number of valves being
placed. Also, the compliance within the prosthetic valve is
variable and dystrophic calciﬁcation is a further problem in
the long term. In general, the durability of biological tissue
after human implantation remains a signiﬁcant problem,
which has not improved over the past 30 years.14
There are logistical advantages of stented endovenous
valve transfer. These are prevention of secondary valve ring
dilatation, selectability of the recipient site, the capability to
harvest smaller valves, and multiple valves can be inserted
via the same system.
Selection of suitable patients with adequate valves for
transfer, adequate muscle pump, and adequate landing
zones are a prerequisite for success. The selection of site
deployment may be particularly difﬁcult as pre-operative
duplex and venography may not deﬁne the entrance of
multiple tributaries into the “optimal” site. Ulcers remaining
recalcitrant after valve transfers could be due to extensive
scar tissue formation with poor micro-circulation, relative
calf muscle incompetence, or an insufﬁcient number of
valves to create sufﬁcient deep venous competence. The
signiﬁcance of venous endoleaks remains uncertain, but
must contribute to the degree of reﬂux and chronic venous
hypertension. The fact that they were not detectable
postoperatively indicated that they were of small size or
that they had spontaneously closed.CONCLUSIONS
Endovenous valve transfer can be performed safely with
100% patency, with no loss of competence in 16 sheep for
up to 6 months. The technique uses standard endovascular
techniques and the surgical procedure in both animals and
four human patients is straightforward. Further improve-
ments in the introducing system may allow a less invasive
deployment.FUNDING
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